# TELA Bio, Inc.: overview TELA · Nasdaq · CIK 1561921 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tela.md) · [Financials](/companies/tela/financials.md) · [Filings](/companies/tela/filings.md) · [Insiders](/companies/tela/insiders.md) Latest reported revenue: [$19.3m](/filings/0001104659-26-094039.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-094039). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [19.0](/filings/0001104659-25-112476.md) | [17.6 d](/filings/0001104659-26-034507.md) | [18.5](/filings/0001104659-26-060234.md) | [20.2](/filings/0001104659-26-094039.md) | [20.7](/filings/0001104659-25-112476.md) | [20.9 d](/filings/0001104659-26-034507.md) | [19.1](/filings/0001104659-26-060234.md) | [19.3](/filings/0001104659-26-094039.md) | | Gross margin | % | [67.8%](/filings/0001104659-25-112476.md) | [63.6% d](/filings/0001104659-26-034507.md) | [67.6%](/filings/0001104659-26-060234.md) | [69.8%](/filings/0001104659-26-094039.md) | [67.5%](/filings/0001104659-25-112476.md) | [65.9% d](/filings/0001104659-26-034507.md) | [65.7%](/filings/0001104659-26-060234.md) | [72.3%](/filings/0001104659-26-094039.md) | | Operating margin | % | [(49.4%)](/filings/0001104659-25-112476.md) | [(47.3%) d](/filings/0001104659-26-034507.md) | [(56.5%)](/filings/0001104659-26-060234.md) | [(45.0%)](/filings/0001104659-26-094039.md) | [(36.5%)](/filings/0001104659-25-112476.md) | [(31.9%) d](/filings/0001104659-26-034507.md) | [(55.2%)](/filings/0001104659-26-060234.md) | [(48.1%)](/filings/0001104659-26-094039.md) | | Net margin | % | [(54.7%)](/filings/0001104659-25-112476.md) | [(52.2%) d](/filings/0001104659-26-034507.md) | [(60.8%)](/filings/0001104659-26-060234.md) | [(49.1%)](/filings/0001104659-26-094039.md) | [(41.6%)](/filings/0001104659-25-112476.md) | [(43.3%) d](/filings/0001104659-26-034507.md) | [(64.4%)](/filings/0001104659-26-060234.md) | [(58.4%)](/filings/0001104659-26-094039.md) | | Diluted EPS | $ per share | [(0.42)](/filings/0001104659-25-112476.md) | not reported | [(0.25)](/filings/0001104659-26-060234.md) | [(0.22)](/filings/0001104659-26-094039.md) | [(0.19)](/filings/0001104659-25-112476.md) | not reported | [(0.21)](/filings/0001104659-26-060234.md) | [(0.20)](/filings/0001104659-26-094039.md) | | Free cash flow | $m | [(9.1) d](/filings/0001104659-25-112476.md) | [(7.8) d](/filings/0001104659-26-034507.md) | [(9.8)](/filings/0001104659-26-060234.md) | [(8.0) d](/filings/0001104659-26-094039.md) | [(5.9) d](/filings/0001104659-25-112476.md) | [(5.0) d](/filings/0001104659-26-034507.md) | [(11.3)](/filings/0001104659-26-060234.md) | [(9.4) d](/filings/0001104659-26-094039.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [29.5](/filings/0001558370-24-003782.md) | [41.4](/filings/0001558370-25-003460.md) | [58.5](/filings/0001104659-26-034507.md) | [69.3](/filings/0001104659-26-034507.md) | [80.3](/filings/0001104659-26-034507.md) | | Gross margin | % | [63.9%](/filings/0001558370-24-003782.md) | [65.3%](/filings/0001558370-25-003460.md) | [68.6%](/filings/0001104659-26-034507.md) | [67.1%](/filings/0001104659-26-034507.md) | [67.7%](/filings/0001104659-26-034507.md) | | Operating margin | % | [(100.0%)](/filings/0001558370-24-003782.md) | [(94.2%)](/filings/0001558370-25-003460.md) | [(75.4%)](/filings/0001104659-26-034507.md) | [(49.2%)](/filings/0001104659-26-034507.md) | [(42.0%)](/filings/0001104659-26-034507.md) | | Net margin | % | [(112.9%)](/filings/0001558370-24-003782.md) | [(106.9%)](/filings/0001558370-25-003460.md) | [(79.8%)](/filings/0001104659-26-034507.md) | [(54.6%)](/filings/0001104659-26-034507.md) | [(48.4%)](/filings/0001104659-26-034507.md) | | Diluted EPS | $ per share | [(2.30)](/filings/0001558370-24-003782.md) | [(2.72)](/filings/0001558370-25-003460.md) | [(2.04)](/filings/0001104659-26-034507.md) | [(1.33)](/filings/0001104659-26-034507.md) | [(0.83)](/filings/0001104659-26-034507.md) | | Free cash flow | $m | [(31.1)](/filings/0001558370-24-003782.md) | [(41.6)](/filings/0001558370-25-003460.md) | [(41.5)](/filings/0001104659-26-034507.md) | [(42.6)](/filings/0001104659-26-034507.md) | [(28.7)](/filings/0001104659-26-034507.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tela/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Essex Woodlands Management, Inc.](/funds/1542339.md) | 2026-06-30 | $5.8m | 7,714,709 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $4.4m | 5,894,114 | | Added +750,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $4.4m | 5,894,114 | | Added +750,000 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $2.0m | 2,662,427 | | Added +45,175 | | [SILVERARC CAPITAL MANAGEMENT, LLC](/funds/1816307.md) | 2026-06-30 | $1.6m | 2,137,201 | | Reduced −122,111 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.2m | 1,568,218 | | Added +27,594 | | [DAFNA Capital Management LLC](/funds/1389933.md) | 2026-06-30 | $1.1m | 1,441,029 | | Unchanged | | [PERKINS CAPITAL MANAGEMENT INC](/funds/884300.md) | 2026-06-30 | $1.0m | 1,375,042 | | Reduced −43,286 | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $477.2k | 636,300 | | Unchanged | | [WealthTrust Axiom LLC](/funds/1425949.md) | 2026-06-30 | $343.3k | 457,734 | | Added +80,796 | ## Recent filings [All 543 filings](/companies/tela/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 20:05 ET | [8-K](/filings/0001104659-26-114695.md) | 5.07 Shareholder vote results | 0001104659-26-114695 | | 2026-10-06 | 20:05 ET | [8-K](/filings/0001104659-26-114042.md) | 8.01 Other events | 0001104659-26-114042 | | 2026-10-05 | 12:05 ET | [8-K](/filings/0001104659-26-113506.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-113506 | | 2026-09-29 | 20:05 ET | [8-K](/filings/0001104659-26-111920.md) | 1.01 Entry into a material agreement | 0001104659-26-111920 | | 2026-09-18 | 20:05 ET | [8-K](/filings/0001104659-26-108935.md) | 3.01 Delisting notice | 0001104659-26-108935 | | 2026-09-14 | 20:05 ET | [DEF 14A](/filings/0001104659-26-107491.md) | Proxy statement, period 2026-10-08 | 0001104659-26-107491 | | 2026-08-31 | 11:05 ET | [8-K](/filings/0001104659-26-103548.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-103548 | | 2026-08-13 | 20:05 ET | [8-K/A](/filings/0001104659-26-095892.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-095892 | | 2026-08-11 | 20:05 ET | [10-Q](/filings/0001104659-26-094039.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094039 | | 2026-08-10 | 20:12 ET | [8-K](/filings/0001104659-26-093371.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-093371 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034507.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/dd9942d3-1dd8-432f-96a9-e95739fb510b) ## About the filer - CIK: 1561921 - Tickers: TELA - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.